Skip to content

Valippu(seizure) in children

ROLE OF JATHIKAAI MATHIRAI IN VALIPPU (JUVENILE SEIZURE DISORDER)

Status
Recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/05/019442
Enrollment
30
Registered
2019-05-30
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G89-G99- Other disorders of the nervous system

Interventions

Intervention1: JATHIKAAI MATHIRAI(Internal): JATHIKAAI MATHIRAI is multi herbal formulation in a dosage of 1 tablet (od) for 48 days Control Intervention1: nil: nil

Sponsors

Dr K Rajeswari
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: children those who have failed to give anticipated results in existing anti epileptic drugs. tonic clonic convulsion loss of conciousness during episode of seizure muscle stiffness jerky movements

Exclusion criteria

Exclusion criteria: status epilepticus metabolic convulsions convulsive disorder associated with other systemic disease children with any pre exiting major organ failure nerocysticercosis meningitis

Design outcomes

Primary

MeasureTime frame
efficacy of the trail drug is measured by hague seizure severity scale (HASS) through quality of life in chilhood epilepsy questionnaire (QOLCE)Timepoint: 1-48 days

Secondary

MeasureTime frame
reduction in the intensity and frequency of seizure in childrenTimepoint: 1-48 days

Countries

India

Contacts

Public ContactDr K Vennila

national institute of sidhha

mmssiddha@gmail.com9444214582

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026